{"id":389414,"date":"2020-11-30T08:03:32","date_gmt":"2020-11-30T13:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389414"},"modified":"2020-11-30T08:03:32","modified_gmt":"2020-11-30T13:03:32","slug":"kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/","title":{"rendered":"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW HAVEN, Conn., Nov.  30, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JkVyeWq71lVWlGfpKCBPJTh8F4Ho3vd5ND7JKVVOe-EFUaeZOkKOuk1LjPjdeswTvXMROlexeGY3jv2WwIpaPSncrE0i899ULSkN5bTmlNY1Rxi8BjHEjQoNbFYCarx6\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Kleo Pharmaceuticals, Inc.<\/a>, a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan\u00ae) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62<sup>nd<\/sup> American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020.<\/p>\n<p>Details of the electronic presentation are as follows:<\/p>\n<p>\n        <strong>Title:<\/strong> KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab<br \/><strong>Number:<\/strong> 3009<br \/><strong>Presenter:<\/strong> Christian Vidal, PhD<br \/><strong>Program:<\/strong> Oral and Poster Abstracts<br \/><strong>Session:<\/strong> 625. Lymphoma: Pre-Clinical\u2014Chemotherapy and Biologic Agents: Poster III<br \/><strong>Time and Location:<\/strong> Monday, December 7, 2020: 7:00 a.m. &#8211; 3 p.m. PST<br \/>Poster Hall (Virtual Meeting)<\/p>\n<p>Kleo\u2019s MATE platform enables site-directed chemical conjugation with off-the-shelf therapeutic antibodies to rapidly add or improve functionality to existing therapies. By MATE-ing a CD3 binder to rituximab, an anti-CD20 therapeutic monoclonal antibody used to treat B-cell lymphomas and lymphocytic leukemias, Kleo is able to retain rituximab\u2019s existing mechanisms of action while adding potent and specific activation of T cells to destroy the tumor. In addition to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tQgtfkQXQLPinWY8I8BTKOemDdwPebd_CkEYltvT95AudwWzQ5NNml-bnGOo-oc5ZsUWcZvIVfc7Wvr9CYAJbZ200dS4fkYl1-vvNEtXB1GtMcxVuiMTv4TE6Lj--QzIlDTUURYrTYVCpeH7WNyFd1OunmTstdKuXC_qB-Rz1jr1HjFpeHoXtC0icMaRkk09rcGHVzJUjwFS2ZkqXH0fTl_IsUjjo3SCXJ7qto0NJF3FwlFLwzRCzpUiiavTDN9t9WYzYNwK45ZkhxHMILDOKe7s26BkRf2eTWUDdTGoUNkMJ06ywimEs316KrZtnm72Uz2eNqvRj80jNceVJ6kOiw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">oncology<\/a> applications, the MATE platform is also being used to develop Kleo\u2019s COVID-19 hyperimmune globulin mimic (HGM) therapy.<\/p>\n<p>\n        <strong>About Kleo Pharmaceuticals, Inc.<\/strong><br \/>\n        <br \/>Kleo Pharmaceuticals is a targeted immunotherapy company that develops fully synthetic bispecific therapies to redirect, enhance or replace antibodies. The company was founded on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleo\u2019s synthetic immunotherapy platform uses two chemistry-based approaches \u2013 antibody-redirecting molecule (ARM) and multi-targeted antibody therapy enhancer (MATE) &#8211; that help redirect and stimulate key components of the immune system to eradicate cancer cells and virulent pathogens. Compared to biologic therapies, Kleo\u2019s compounds are smaller and more versatile, allowing for better tumor\/tissue penetration, non-immunogenic for improved safety and higher dose levels, more efficient to produce and potentially orally bioavailable. They can be optimized against specified biological targets or combined with existing cell- or antibody-based therapies. Kleo investors include Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (Nikkei:PPTDF). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yd0dOOIIHCUT5Str11xOZHstccPAWhy9TQp9c1YhcdmF3HiY-D2B1sFx3t8V4buGWM_MPn9-ML-POismidXNy5K2_fQ6Nsb3a6nNnzZVeQIOBimumyCuq89OEEpEcM2b\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.kleopharmaceuticals.com<\/a>.<\/p>\n<p>CONTACT INFORMATION <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GbdIeP2T-RqkLccMlYBfk1iEh_jzYkhrjvyEvk_hPn0U03tuiuvcLis6FLQFAm0qJKBfadmzKOGblMtnRZe6rnOPOzzFtYxUNqEN-tgVKZA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LifeSci Advisors<\/a> (Investors)<br \/>Irina Koffler<br \/>646-970-4681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UDF23zyD-ShqREyWUmxHMgIP_lya-CKk2SbJy0YtvHFhU46lU90OWv1hHhq4iPHvQTzAJYM-v0cQSpF_Y2reHeJquRIac5Grmrc8PhpTNg7XGcIJfeBr7lMY0IHglZue\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ikoffler@lifesciadvisors.com<\/a><\/p>\n<p>Susan Kinkead (Media)<br \/>415-509-3610<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fco7kmc-7MZAAgyuOncKlZcH9LmfTtX1xHhHLmUws5lfTOzE1209VphHsLvQTEMKzFXd-hOkt1IIuypsKqmAPfC_IIHOt8mYs9dAvFHDlws=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">susan@kinkeadcomm.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c7567bcb-d356-4326-a2fb-5018e845cde9\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan\u00ae) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020. Details of the electronic presentation are as follows: Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389414","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan\u00ae) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020. Details of the electronic presentation are as follows: Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity &hellip; Continue reading &quot;Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T13:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting\",\"datePublished\":\"2020-11-30T13:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/\"},\"wordCount\":439,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/\",\"name\":\"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==\",\"datePublished\":\"2020-11-30T13:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting - Market Newsdesk","og_description":"NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan\u00ae) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020. Details of the electronic presentation are as follows: Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity &hellip; Continue reading \"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T13:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting","datePublished":"2020-11-30T13:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/"},"wordCount":439,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/","name":"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==","datePublished":"2020-11-30T13:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTc5NyMzODQyODMzIzUwMDA3MTY0MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kleo-pharmaceuticals-announces-data-presentation-on-kpmw135-a-novel-cd3-x-cd20-bispecific-molecule-and-conjugation-platform-mate-at-the-62nd-annual-society-of-hematology-ash-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE\u2122) at The 62nd Annual Society of Hematology (ASH) Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389414"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389414\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}